Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 64

Results For "2023"

1090 News Found

Fortis Healthcare Q1 FY24 consolidated PAT drops at Rs. 111.76 Cr
News | August 06, 2023

Fortis Healthcare Q1 FY24 consolidated PAT drops at Rs. 111.76 Cr

Fortis Healthcare has reported total income of Rs. 1665.55 crores during the period ended June 30, 2023


Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr
News | August 06, 2023

Indraprastha Medical Corporation Q1 FY24 PAT up at Rs. 30.50 Cr

The company has reported total income of Rs. 310.07 crores during the period ended June 30, 2023


Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma
Drug Approval | August 06, 2023

Briefs: Dr. Reddy's Laboratories and Aurobindo Pharma

The inspection closed with zero observations and a classification of No Action Indicated


Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
Drug Approval | August 05, 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023


USFDA approves Merck’s ERVEBO for use in children 12 months of age and older
Drug Approval | August 05, 2023

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease


Zydus Wellness posts Q1 FY24 consolidated PAT at Rs. 110.4 Cr
News | August 04, 2023

Zydus Wellness posts Q1 FY24 consolidated PAT at Rs. 110.4 Cr

The company has reported total income of Rs. 704.5 crores during the period ended June 30, 2023


Dabur India posts Q1 FY24 PAT at Rs. 463.88 Cr
News | August 04, 2023

Dabur India posts Q1 FY24 PAT at Rs. 463.88 Cr

The company has posted net profit of Rs. 463.88 crores for the period ended June 30, 2023


Lupin posts Q1 FY24 consolidated PAT at Rs. 452.26 Cr
News | August 04, 2023

Lupin posts Q1 FY24 consolidated PAT at Rs. 452.26 Cr

The company has reported total income of Rs. 4836.89 crores during the period ended June 30, 2023


Piramal Pharma posts Q1 FY24 consolidated loss at Rs. 98.58 Cr
News | August 04, 2023

Piramal Pharma posts Q1 FY24 consolidated loss at Rs. 98.58 Cr

The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023


Jagsonpal Pharmaceuticals posts Q1 FY2024 PAT at Rs. 7.47 Cr
News | August 03, 2023

Jagsonpal Pharmaceuticals posts Q1 FY2024 PAT at Rs. 7.47 Cr

The company has reported total income of Rs. 62.15 crores during the period ended June 30, 2023